Stockscreener 앱 받기
2.58
6.52%
-0.18
시간 외 거래:
2.58
전일 마감가:
$2.76
열려 있는:
$2.82
하루 거래량:
2.56M
Relative Volume:
1.94
시가총액:
$289.04M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-0.4971
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
-37.83%
1개월 성능:
-47.13%
6개월 성능:
-85.96%
1년 성능:
-74.30%
1일 변동 폭
$2.56
$2.82
1주일 범위
$2.56
$4.45
52주 변동 폭
$2.56
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
2.58 | 289.04M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 개시 | Stifel | Buy |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman Sachs | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenheim | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Phathom Pharmaceuticals Q1 2025 Financial Results - TradingView
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
BlackRock, Inc. Reduces Stake in Phathom Pharmaceuticals Inc. - GuruFocus
Phathom Pharmaceuticals Inc [PHAT] CFO and CBO makes an insider sale of 3,678 shares worth $16740.0. - knoxdaily.com
Uncovering the Potential of Phathom Pharmaceuticals Inc (PHAT) Stock - investchronicle.com
Upward Trajectory: Phathom Pharmaceuticals Inc (PHAT) Posts a Slidee, Closing at 4.11 - DWinneX
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting - GlobeNewswire
Groundbreaking GERD Treatment VOQUEZNA: First Real-World Data Release Coming at DDW 2025 - Stock Titan
Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday - Defense World
Phathom Pharmaceuticals Inc [PHAT] Shares Fall Approximately -55.18% Over the Year - knoxdaily.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Geode Capital Management LLC Acquires 155,577 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
SNL’s Kenan Thompson brings comedy chops to Phathom’s Voquezna campaign - Medical Marketing and Media
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 - The Manila Times
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals to Host Live Webcast for Q1 2025 Financial Results and Business Update on May 1, 2025 - Nasdaq
Phathom Pharmaceuticals To Report First Quarter 2025 Financial Results And Provide Business Update On Thursday, May 1, 2025 - marketscreener.com
Phathom Pharmaceuticals to Report First Quarter 2025 - GlobeNewswire
Phathom Pharmaceuticals Q1 Earnings Preview: Key VOQUEZNA Sales Data and Growth Strategy Reveal - Stock Titan
Phathom Pharmaceuticals COO Nabulsi sells $51,956 in stock - MSN
Shares In Phathom Pharmaceuticals Inc (PHAT) -51.97% Down, YTD - Marketing Sentinel
Phathom Pharmaceuticals (NASDAQ:PHAT) Given “Buy” Rating at Needham & Company LLC - Defense World
Phathom Pharmaceuticals Inc’s Market Journey: Closing Weak at 4.03, Down -4.62 - DWinneX
Alliancebernstein L.P. Has $370,000 Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
The Goldman Sachs Group Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $10.00 - Defense World
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phathom Pharmaceuticals Inc 주식 (PHAT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
| Henderson Molly | CFO and CBO |
Jan 21 '25 |
Sale |
6.59 |
6,583 |
43,371 |
93,546 |
| Nabulsi Azmi | Chief Operating Officer |
Jan 21 '25 |
Sale |
6.59 |
7,886 |
51,957 |
233,390 |
| Curran Terrie | President and Chief Executive |
Jan 21 '25 |
Sale |
6.59 |
19,109 |
125,884 |
360,465 |
| Nabulsi Azmi | Chief Operating Officer |
Dec 19 '24 |
Sale |
8.00 |
1,118 |
8,944 |
239,303 |
| Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
| KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
| Parikh Asit | Director |
Dec 13 '24 |
Buy |
8.12 |
10,000 |
81,248 |
75,500 |
| Nabulsi Azmi | Chief Operating Officer |
Jul 15 '24 |
Sale |
11.72 |
10,901 |
127,760 |
240,421 |
0.39%
3.66%
자본화:
|
볼륨(24시간):